This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The FDA has approved Sanofis Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar product for the treatment of diabetes. Merilog is a biosimilar to Novo Nordisks NovoLog, a widely used rapid-acting insulin aspart. Insulin, a hormone produced by the pancreas, allows glucose to enter cells for energy.
Medtronic has expanded a Class I recall of remote controllers used with the MiniMed 508 insulin pump or the MiniMed Paradigm family of insulin pumps over potential cybersecurity risks. The medtech giant has also expanded another Class I recall of the retainer rings on its 600 series insulin pumps.
The treatment is derived from deceased donor pancreatic cells and is indicated for patients who are unable to achieve average blood glucose levels (glycated hemoglobin) with daily insulin injections or with continuous infusion through a pump because of repeated episodes of severe hypoglycemia (low blood sugar).
On July 31, 2021, Health Canada published a Notice of Intent outlining its plan to amend the Food and Drug Regulations ( FDR ) and the Medical Devices Regulations in the spring of 2022. Health Canada is accepting comments on the Minister of Health’s proposal to amend the FDR and the Medical Devices Regulations until October 28, 2021.
Amylin, a hormone co-secreted with insulin, plays a key role in regulating appetite by enhancing leptins effects the hormone that signals fullness after eating. Petrelintide, Zealand Pharmas long-acting amylin analog, is currently in Phase II clinical development and is designed for once-weekly subcutaneous injections.
GLP-1 receptor agonists, or incretin (metabolic hormones) mimetics, are analogs of the GLP-1 peptide hormone that binds to the GLP-1 receptor to regulate blood sugar levels by boosting insulin secretion. dependent insulin secretion and suppression of glucagon release. What Are GLP-1 Agonists? mediated glucose?dependent
The body becomes resistant to insulin and can no longer use glucose properly as a fuel, so glucose begins circulating in the bloodstream and may lead to problems with the circulatory, nervous and immune systems. Often, diabetes medication or insulin therapy are used as management tools.
The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare. It’s much needed. It’s a hot area.”
Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas. Amylin helps regulate satiety and slows gastric emptying, which can support weight loss.
The study , published yesterday in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism , revealed that two helpings of fruit led to higher measures of insulin sensitivity than those who ate less than half a serving. Diabetes is a growing health problem globally. Keep it Fresh.
Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. Agonist engagement of the receptor is involved in insulin and glucose regulation, and hence has therapeutic implications for diseases like diabetes and obesity.
Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. Agonist engagement of the receptor is involved in insulin and glucose regulation, and hence has therapeutic implications for diseases like diabetes and obesity.
While there are currently six biosimilars for AbbVie’s Humira (adalimumab) that have been approved by the regulator, the company’s patents prevent biosimilars from being launched until 2023. The regulator allows biosimilars to show slight differences in clinically inactive components of a product.
Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, lifesciences and pharmaceutical sectors. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the fourth quarter and decreased 56.7 from $289.36.
Efruxifermin is a novel Fc-FGF21 fusion protein designed to emulate the activity of native FGF21, an endogenous hormone that regulates metabolism and alleviates cellular stress. It not only reduces liver fat and inflammation but can also reverse fibrosis, enhance insulin sensitivity and improve lipid profiles.
Beyond this, there are other factors within the control of the healthcare and lifesciences industries that will determine how ubiquitous self care actually becomes. The audit shows that product safety, efficacy and regulation are the primary drivers of trust in self-care. Self-care via TikTok.
XTALKS WEBINAR: Review of Key Trends for LifeScience Commercial Teams in 2023 Register for this free on-demand webinar to learn about the latest trends in sales and marketing campaigns that could help bolster commercial success for lifescience companies this year.
Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist.
Revita, an outpatient endoscopic procedural therapy, which aims to eliminate insulin needs and enhance glycemic control by ablating dysfunctional duodenal mucosa. Fractyl Health has initiated discussions with European regulators to establish an investigational new drug (IND)-enabling pathway for RJVA-001 in the treatment of T2D.
In September 2022, Roche acquired Good Therapeutics for an upfront payment of $250 million, and has access to their PD-1-regulated IL-2 program. It is a dipeptidyl peptidase-4 inhibitor that keeps insulin levels stable and reduces the amount of glucose produced by the body. Merck’s total global revenue from Lagevrio was $5.68
They mimic the action of GLP-1, a hormone that helps regulate blood sugar levels by enhancing insulin secretion. GLP-1 agonists/inhibitors work by slowing digestion to suppress appetite but can cause problems if that process slows down too much.
Often, the potential patient pool for a given trial is small and the unmet need is high, incentivizing drugmakers and regulators to find innovative ways to make game-changing therapeutics available to those who need them most. Also known as Berardinelli-Seip syndrome, there are four subtypes of lipodystrophy.
Internationally, Medtronic expanded its MiniMed 780G insulin pump and Guardian 4 sensor. Significantly, Roche received full compliance under the In-Vitro Diagnostic Medical Devices Regulation (IVDR) from the European Union. It also plans to launch these products in the US.
This disparity can be attributed to various factors, including the lack of government regulation on drug prices and the complex web of negotiations between drug manufacturers, insurers and pharmacy benefit managers. Americans consistently pay more for prescription drugs than people in other developed countries.
From blockbuster drugs like Ozempic to foundational treatments like insulin, these therapies showcase the diverse strategies used by pharma companies to meet the needs of a rapidly growing market. Price of Insulin: Varies significantly by type and brand of insulin. The company is targeting revenue of $40.4 billion to $41.6
The injection is intended to regulate blood sugar, in conjunction with diet and exercise, in adults with type 2 diabetes. Lifescience industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 percent more than placebo when used in combination with a long-acting insulin.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content